human cancer modeling: recapitulating tumor heterogeneity towards personalized medicine

Human Cancer Modeling: Recapitulating Tumor Heterogeneity Towards Personalized Medicine

Despite diagnostic, preventive and therapeutic advances, growing incidence of cancer and high rate of mortality among patients affected by specific cancer types indicate current clinical measures are not ideally useful in eradicating cancer. Chemoresistance and subsequent disease relapse are believed to be mainly driven by the cell-molecular heterogeneity of human tumors that necessitates perso...

Human Cancer Modeling: Recapitulating Tumor Heterogeneity Towards Personalized Medicine

Despite diagnostic, preventive and therapeutic advances, growing incidence of cancer and high rate of mortality among patients affected by specific cancer types indicate current clinical measures are not ideally useful in eradicating cancer. Chemoresistance and subsequent disease relapse are believed to be mainly driven by the cell-molecular heterogeneity of human tumors that necessitates perso...

Tumor heterogeneity and personalized medicine.

In the past 10 years, the number of tools available to treat cancer has increased, as has our understanding of what makes some cancers tick. The standard old-time cancer treatments were largely predicated on attacking DNA, an approach fueled by the belief that tumor cells divide more rapidly than normal cells. However, with the notable exception of Burkitt’s lymphoma, only a small percentage of...

Tumor heterogeneity has important consequences for personalized medicine in ovarian cancer.

Most patients with ovarian cancers relapse, and treatment failure has often been attributed to chemoresistance in tumor cells. Emerging evidence indicates that tumor heterogeneity may play an equally important role. Although the idea of tumor heterogeneity is not new, little attention has been focused on applying it to understand and control ovarian cancer progression. Recent advances in unders...

Genetic heterogeneity in breast cancer: the road to personalized medicine?

More women die from breast cancer across the world today than from any other type of malignancy. The clinical course of breast cancer varies tremendously between patients. While some of this variability is explained by traditional clinico-pathological factors (including patient age, tumor stage, histological grade and estrogen receptor status), molecular profiling studies have defined breast ca...

Towards personalized medicine..